These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 29905865)

  • 1. Impact of Naturally Occurring Variation in the Human Papillomavirus 58 Capsid Proteins on Recognition by Type-Specific Neutralizing Antibodies.
    Godi A; Martinelli M; Haque M; Li S; Zhao Q; Xia N; Cocuzza CE; Beddows S
    J Infect Dis; 2018 Oct; 218(10):1611-1621. PubMed ID: 29905865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.
    Godi A; Boampong D; Elegunde B; Panwar K; Fleury M; Li S; Zhao Q; Xia N; Christensen ND; Beddows S
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32967963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of naturally occurring variation in the human papillomavirus 52 capsid proteins on recognition by type-specific neutralising antibodies.
    Godi A; Bissett SL; Masloh S; Fleury M; Li S; Zhao Q; Xia N; Cocuzza CE; Beddows S
    J Gen Virol; 2019 Feb; 100(2):237-245. PubMed ID: 30657447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of naturally occurring variation in the human papillomavirus (HPV) 33 capsid proteins on recognition by vaccine-induced cross-neutralizing antibodies.
    Godi A; Bissett SL; Miller E; Beddows S
    J Gen Virol; 2017 Jul; 98(7):1755-1761. PubMed ID: 28691664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype.
    Bissett SL; Godi A; Fleury MJ; Touze A; Cocuzza C; Beddows S
    J Virol; 2015 Aug; 89(15):7748-57. PubMed ID: 25995264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naturally Occurring Major and Minor Capsid Protein Variants of Human Papillomavirus 45 (HPV45): Differential Recognition by Cross-Neutralizing Antibodies Generated by HPV Vaccines.
    Godi A; Facchetti A; Bissett SL; Cocuzza C; Miller E; Beddows S
    J Virol; 2015 Dec; 90(6):3247-52. PubMed ID: 26719255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity of Human Papillomavirus (HPV) Lineage and Sublineage Variant Pseudoviruses to Neutralization by Nonavalent Vaccine Antibodies.
    Godi A; Kemp TJ; Pinto LA; Beddows S
    J Infect Dis; 2019 Nov; 220(12):1940-1945. PubMed ID: 31412122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crystal Structures of Two Immune Complexes Identify Determinants for Viral Infectivity and Type-Specific Neutralization of Human Papillomavirus.
    Li Z; Wang D; Gu Y; Song S; He M; Shi J; Liu X; Wei S; Li J; Yu H; Zheng Q; Yan X; Baker TS; Zhang J; McLellan JS; Li S; Xia N
    mBio; 2017 Sep; 8(5):. PubMed ID: 28951471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2.
    Seitz H; Schmitt M; Böhmer G; Kopp-Schneider A; Müller M
    Int J Cancer; 2013 Feb; 132(3):E139-48. PubMed ID: 22961598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody Competition Reveals Surface Location of HPV L2 Minor Capsid Protein Residues 17-36.
    Bywaters SM; Brendle SA; Tossi KP; Biryukov J; Meyers C; Christensen ND
    Viruses; 2017 Nov; 9(11):. PubMed ID: 29125554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting synthetic Human Papillomavirus (HPV) L2 disulfide-induced N-terminus conformational epitopes for pan-HPV vaccine development.
    Khanal S; Ferraris ED; Zahin M; Joh J; Ghim SJ; Jenson AB
    Exp Mol Pathol; 2015 Oct; 99(2):330-4. PubMed ID: 26134615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations on the FG surface loop of human papillomavirus type 16 major capsid protein affect recognition by both type-specific neutralizing antibodies and cross-reactive antibodies.
    Carpentier GS; Fleury MJ; Touzé A; Sadeyen JR; Tourne S; Sizaret PY; Coursaget P
    J Med Virol; 2005 Dec; 77(4):558-65. PubMed ID: 16254978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16.
    Varsani A; Williamson AL; de Villiers D; Becker I; Christensen ND; Rybicki EP
    J Virol; 2003 Aug; 77(15):8386-93. PubMed ID: 12857908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation and properties of a papillomavirus infectious intermediate and its utility for neutralization studies.
    Wang JW; Jagu S; Kwak K; Wang C; Peng S; Kirnbauer R; Roden RB
    Virology; 2014 Jan; 449():304-16. PubMed ID: 24418565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional assessment and structural basis of antibody binding to human papillomavirus capsid.
    Zhang X; Li S; Modis Y; Li Z; Zhang J; Xia N; Zhao Q
    Rev Med Virol; 2016 Mar; 26(2):115-28. PubMed ID: 26676802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types.
    Christensen ND; Cladel NM; Reed CA; Budgeon LR; Embers ME; Skulsky DM; McClements WL; Ludmerer SW; Jansen KU
    Virology; 2001 Dec; 291(2):324-34. PubMed ID: 11878901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of Surface-Exposed Loops on the HPV16 Capsid to Antigenic Domains Recognized by Vaccine or Natural Infection Induced Neutralizing Antibodies.
    Godi A; Vaghadia S; Cocuzza C; Miller E; Beddows S
    Microbiol Spectr; 2022 Jun; 10(3):e0077922. PubMed ID: 35475682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
    Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
    Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralization sites of human papillomavirus-6 relate to virus attachment and entry phase in viral infection.
    Liu X; Chen J; Wang Z; Wang D; He M; Qian C; Song S; Chi X; Kong Z; Zheng Q; Wang Y; Yu H; Zhao Q; Zhang J; Li S; Gu Y; Xia N
    Emerg Microbes Infect; 2019; 8(1):1721-1733. PubMed ID: 31769733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.